Immunotherapy for Head and Neck Cancer:Mechanisms,Challenges,and Future Perspectives  

作　　者：Sakthi Sanjana Deenadhayalan Elizabeth Rani Edwin Karthikeyan Elumalai 

机构地区：[1]Department of Pharmaceutical Chemistry,Saveetha Institute of Medical and Technical Sciences,Chennai 602105,Tamilnadu,India

出　　处：《Journal of Bio-X Research》2024年第4期158-164,共7页生物组学研究杂志(英文)

摘　　要：Immunotherapy has emerged as a promising approach for treating head and neck neoplasms,with the potential to improve patient outcomes and revolutionize cancer treatment.This review discusses the current evidence supporting the use of immunotherapy for head and neck cancer and outlines future research directions.Immunotherapy uses mostly immune checkpoint inhibitors,such as those that work on the PD-1/PD-L1 axis and CTLA-4,to improve the ability of the immune system to fight cancer cells.PD-1/PD-L1 inhibitors,such as pembrolizumab and nivolumab,have been shown to work in clinical trials,which is why they have been approved for some people with head and neck cancer.These treatments reactivate the immune response against tumors,resulting in tumor reduction and improved survival rates.CTLA-4 inhibition has shown promise in enhancing the immune system’s ability to combat head and neck cancer cells,although its efficacy has been more pronounced in melanoma treatment.Ongoing research focuses on improving immunotherapy efficacy,identifying biomarkers to predict patient responses,and developing personalized treatment strategies.Clinical trials have documented marked increases in survival rates and decreases in tumor size,highlighting the effectiveness of targeted approaches.As scientific advancements progress,personalized immunotherapy strategies may soon become accessible,enabling the customization of treatment plans for individual patients with head and neck cancer.

关 键 词：IMMUNOTHERAPY head neck neoplasmswith biomarkers head neck cancer immune checkpoint inhibitors 

分 类 号：R739.91[医药卫生—肿瘤]